1.5 CE Test Hours Caring for Survivors of Hodgkin LymphomaContrada, EmilyAJN The American Journal of Nursing: February 2019 - Volume 119 - Issue 2 - p 42 doi: 10.1097/01.NAJ.0000553182.20449.5e Feature Articles Free CE Article OutlineOutline Article MetricsMetrics TEST INSTRUCTIONS PROVIDER ACCREDITATION PAYMENT Caring for Survivors of Hodgkin Lymphoma GENERAL PURPOSE: LEARNING OBJECTIVES/OUTCOMES: Back to Top | Article Outline TEST INSTRUCTIONS Read the article. Take the test for this CE activity online at www.nursingcenter.com/ce/ajn. You'll need to create and log in to your personal CE Planner account before taking online tests. Your planner will keep track of all your Lippincott Professional Development (LPD) online CE activities for you. There is only one correct answer for each question. The passing score for this test is 14 correct answers. If you pass, you can print your certificate of earned contact hours and the answer key. If you fail, you have the option of taking the test again at no additional cost. For questions, contact LPD: 1-800-787-8985. Registration deadline is December 4, 2020. Back to Top | Article Outline PROVIDER ACCREDITATION LPD will award 1.5 contact hours for this continuing nursing education (CNE) activity. LPD is accredited as a provider of CNE by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 1.5 contact hours. LPD is also an approved provider of CNE by the District of Columbia, Georgia, and Florida #50-1223. Your certificate is valid in all states. Back to Top | Article Outline PAYMENT The registration fee for this test is $17.95. Back to Top | Article Outline Caring for Survivors of Hodgkin Lymphoma GENERAL PURPOSE: To provide information about Hodgkin lymphoma, including current recommendations for survivor surveillance and screening. Back to Top | Article Outline LEARNING OBJECTIVES/OUTCOMES: After completing this continuing education activity, you should be able to outline the etiology and presentation of Hodgkin lymphoma (HL). identify common late adverse treatment effects for survivors of HL. summarize surveillance and screening recommendations for HL survivors. The presence of which of the following types of cells characterizes the classical form of Hodgkin lymphoma (HL)? popcorn Reed–Sternberg lymphocyte predominant Which of the following viral infections might protect against HL? HIV measles Epstein–Barr Patients who have HL typically present with painless and rubbery lymphadenopathy involving which of the following groups of lymph nodes? axillary mediastinal infraclavicular Which of the following symptoms of HL indicates a poorer prognosis? cough chest pain night sweats The chemotherapy regimen most commonly prescribed for adults who have HL includes etoposide. bleomycin. vincristine. The chemotherapy regimen most commonly prescribed for pediatric patients who have HL includes vinblastine. dacarbazine. cyclophosphamide. The leading cause of death among HL survivors is second primary malignancies. pulmonary infection. cardiotoxicity. For female HL survivors with a history of chest irradiation, the National Comprehensive Cancer Network recommends annual breast cancer screening beginning how many years after completing HL treatment? 2 to 4 5 to 7 8 to 10 Patients who receive chest radiation of 30 Gy or more have a lung cancer risk that is how many times greater than those who receive chest radiation of less than 5 Gy? 4 to 6 7 to 9 10 to 12 The leading noncancer-related cause of death among HL survivors is cardiovascular disease. pulmonary disease. endocrine disease. According to Henson and colleagues, which of the following accounts for 74% of cardiovascular-related deaths among HL survivors over age 60? ischemic heart disease cardiac dysrhythmias cardiomyopathy Significant risk factors for developing cardiovascular late effects of anthracycline therapy include older age. male sex. cumulative doses of 500 mg/m2 or more. Jones and colleagues reported that which of the following was associated with a 51% reduced risk of any cardiovascular event among adult HL survivors? a low-fat diet regular vigorous exercise use of antioxidant supplements A possible alternative to costly coronary angiography for screening patients at low-to-intermediate risk for developing coronary artery disease after HL treatment is serial coronary artery calcium scores. quarterly cardiac stress tests. measuring monthly triglyceride levels. Long-term fibrotic changes can result from which of the following complications that may develop 2 to 3 months after chest irradiation in HL survivors? atelectasis emphysema pneumonitis The most common endocrine complication among HL survivors following neck irradiation is Graves’ disease. hypothyroidism. thyrotoxicosis. Women with a history of pelvic or abdominal irradiation for HL may be at risk for preeclampsia. hyperemesis gravidarum. postpartum hemorrhage. Swerdlow and colleagues found that the risk of premature menopause increased 36-fold in women with HL who received both pelvic radiation and chemotherapy with alkylating agents. vinca alkaloids. antitumor antibiotics. A possible late effect associated with vinca alkaloids is cardiomyopathy. peripheral neuropathy. gonadal damage. The Children's Oncology Group guidelines for HL follow-up, which begins 5 years after treatment, recommend an annual dental exam and cleaning. meningococcal vaccination. pulmonary examination. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.